Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups
Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups
复制标题
瑞舒伐他汀治疗对不同年龄组冠状动脉扩张患者的抗炎作用
DOI：
10.1186/s12872-020-01604-z
复制
发表时间：
2020-07-11
影响因子：
2.1
通讯作者：
Li, Rui-Lin
中科院分区：
文献类型：
--
作者：
Fan, Cheng-Hui;Hao, Ying;Li, Rui-Lin
冠状动脉扩张症（coronary artery ectasia，CAE）是冠状动脉异常扩张的一种表现.炎症在动脉粥样硬化的各个阶段都起着重要作用。我们调查了CAE与血清超敏C反应蛋白（hs-CRP）和白细胞介素-6（IL-6）水平的关系，以验证我们的假设，即患者年龄与CAE抗炎治疗的疗效有关。2015年1月1日至2019年7月30日。从患者病历中收集患者的基线数据，包括性别、年龄和高血压、高脂血症和糖尿病病史。研究参与者按年龄分组如下：CAE-A（n = 60，年龄≤ 50岁），CAE-B（n = 83，50岁<年龄≤ 70岁）和CAE-C（n = 74，年龄> 70岁）。此外，有一个控制（NC）组（n = 73）与正常coronary arteries. ResultsAll患者接受口服瑞舒伐他汀治疗（10 mg，QN quaque quantitate）时，他们被诊断为CAE，并保持良好的后续行动，在6个月的随访结束时的损失率为0.0%。NC组接受常规症状缓解治疗和瑞舒伐他汀治疗。在这四组中，CAE患者的炎症标志物hs-CRP和IL-6显著高于NC（p <0.05）。两组间hs-CRP、IL-6水平差异有统计学意义（P = 0.048，P = 0.025）。Logistic回归分析显示hs-CRP（OR = 1.782，95%CI：1.124-2.014，P = 0.021）和IL-6（OR = 1.584，95%CI：1.112-1.986，P = 0.030）是CAE的独立预测因素。CAE-A组炎症标志物高于CAE-B组，CAE-B组高于CAE-C组。6个月后的瑞舒伐他汀治疗的随访显示，在CAE-A组的hs-CRP和IL-6水平的显着更大的减少比在CAE-B组，这再次是更大的CAE-B组比在CAE-C group.ConclusionsAnti-inflammatory therapy使用瑞舒伐他汀是更有效的年轻CAE患者，表明需要早期他汀类药物治疗CAE。
BackgroundCoronary artery ectasia (CAE) is an angiographic finding of abnormal coronary dilatation. Inflammation plays a major role in all phases of atherosclerosis. We investigated the relationship between CAE and serum high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels to test our hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy for CAE.MethodsWe conducted a prospective analysis of 217 patients with CAE treated at the Department of Cardiology, Shanghai East Hospital, Ji’an Campus and the Baoshan People’s Hospital, from January 1, 2015 to July 30, 2019. Baseline data of patients, including sex; age; and history of hypertension, hyperlipidemia, and diabetes, were collected from patient medical records. Study participants were grouped by age as follows: CAE-A (n= 60, age ≤ 50 years), CAE-B (n= 83, 50 years <age ≤ 70 years), and CAE-C (n= 74, age > 70). Additionally, there was a control (NC) group (n= 73) with normal coronary arteries.ResultsAll patients received oral rosuvastatin therapy (10 mg, QN quaque nocte) when they were diagnosed with CAE and maintained good follow-up, with a loss rate of 0.0% at the end of the 6-month follow-up. The NC group received regular symptom-relieving treatments and rosuvastatin therapy. Of these four groups, the inflammatory markers, hs-CRP and IL-6, were significantly higher in patients with CAE than in the NCs (p< 0.05). Post-hoc tests showed that hs-CRP and Il-6 levels had significant differences between the CAE-A and CAE-C groups (P= 0.048,P= 0.025). Logistic regression analysis showed that hs-CRP (OR = 1.782, 95% CI: 1.124–2.014,P= 0.021) and IL-6 (OR = 1.584, 95% CI: 1.112–1.986,P= 0.030) were independent predictors of CAE. The inflammatory markers were higher in the CAE-A group than in the CAE-B group and higher in the CAE-B group than in the CAE-C group. Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in hs-CRP and IL-6 levels in the CAE-A group than in the CAE-B group, which again were greater in the CAE-B group than in the CAE-C group.ConclusionsAnti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy in CAE.